Can you provide a comprehensive overview of CT imaging of the kidneys, ureters, and bladder, including CT KUB and CT urography (nephrographic, excretory, and split‑bolus techniques), with details on technique, reconstructions, Hounsfield unit values, and window settings?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

CT Imaging of Kidneys, Ureters, and Bladder: Comprehensive Overview

CT KUB (Non-Contrast)

CT KUB is the gold standard for detecting urinary stones, with thin-slice acquisition from T10 vertebral body to pubic symphysis to minimize radiation while capturing the entire urinary tract 1, 2.

Technique

  • Scan range: Upper border of T10 to pubic symphysis 2
  • Patient positioning: Supine (prone only if specifically requested) 3
  • Dose parameters:
    • Low-dose: CTDIvol 2-3 mGy for stone detection 4
    • Standard: CTDIvol 5-6 mGy for benign conditions 4
  • Slice thickness: Thin-slice acquisition (typically 1-3mm)

Reconstructions

  • Axial, coronal, and sagittal multiplanar reformations (MPR)
  • Maximum intensity projections (MIP) for stone visualization 1
  • 3D volume rendering when needed 1

HU Values & Windows

  • Stones: >100-200 HU (calcium-based stones typically 400-1000+ HU)
  • Soft tissue window: W:350-400, L:40-50
  • Bone window: W:2000-3000, L:300-500 for stone detection

CT Urography (CTU)

CTU requires unenhanced images followed by IV contrast-enhanced nephrographic and excretory phases (≥5 minutes post-injection), with split-bolus protocols preferred when appropriate to reduce radiation exposure 5, 1, 3.

Standard Multi-Phase Protocol

Phase 1: Unenhanced

  • Same as CT KUB above
  • Detects stones and baseline attenuation
  • CTDIvol 2-3 mGy 4

Phase 2: Nephrographic Phase (70-90 seconds post-injection)

  • Contrast: 100-120 mL at 2.5-3 mL/s
  • Timing: 70-90 seconds after injection
  • Purpose: Optimal renal parenchymal enhancement, mass characterization
  • Expected HU:
    • Renal cortex: 120-180 HU
    • Renal medulla: 80-120 HU
    • Renal vessels: 250-350 HU

Phase 3: Excretory Phase (7-10 minutes post-injection)

  • Timing: Fixed at 7 minutes post-injection (no need for test slices) 3
  • Furosemide: 20 mg IV before contrast is mandatory to improve ureteral opacification 3
  • Purpose: Visualize collecting system, ureters, bladder
  • Expected HU: Opacified urine 100-300 HU

Split-Bolus Protocol (Radiation Reduction)

Split-bolus combines nephrographic and excretory phases into a single acquisition, reducing radiation dose from ~15.6 mGy to ~6.7 mGy 6.

Technique 3, 6

  1. Pre-hydration: 800 mL oral water 20 minutes before scan
  2. First bolus: 50 mL contrast at 2.5 mL/s
  3. Wait: 6 minutes (360 seconds)
  4. Second bolus: 70 mL contrast at 2.5 mL/s
  5. Scan: 60 seconds after second bolus (420 seconds total)

Advantages

  • Single contrast-enhanced acquisition
  • 57% radiation dose reduction 6
  • Virtual unenhanced images can replace true unenhanced (87.5% sensitivity for stones) 6

Limitations

  • Suboptimal for arterial phase evaluation
  • May have incomplete bladder opacification (only 26.2% complete) 6
  • Not ideal when vascular assessment critical

Triple-Bolus Protocol (For UPJO/Vascular Assessment)

For ureteropelvic junction obstruction requiring vascular evaluation, triple-bolus provides superior arteriovenous differentiation 7.

  • Adds arterial phase for crossing vessel assessment
  • Higher HU values in all phases
  • Better arteriovenous differentiation (κ = 0.77) 7

Protocol Selection Algorithm

Use CT KUB (non-contrast only) when:

  • Acute flank pain/suspected stone disease 1
  • Follow-up of known stones
  • No concern for mass or urothelial malignancy

Use Standard Multi-Phase CTU when:

  • Gross hematuria with risk factors for malignancy 5, 4
  • Staging urothelial carcinoma 5
  • Characterizing renal masses
  • Need for arterial phase imaging

Use Split-Bolus CTU when:

  • Age <40 years or lower-risk patients 5
  • Microscopic hematuria evaluation
  • Radiation dose reduction priority 3
  • No need for separate arterial assessment

Use Triple-Bolus CTU when:

  • UPJO with suspected crossing vessels 7
  • Vascular anatomy critical for surgical planning

Reconstructions for CTU

Essential Reconstructions 1, 4

  • Axial images: 1-3mm slice thickness
  • Coronal/sagittal MPR: For anatomic overview
  • MIP: 5-10mm thick slabs for stone/collecting system visualization
  • 3D volume rendering: For surgical planning, vascular anatomy

Advanced Techniques

  • Dual-energy CT: Stone composition analysis, virtual unenhanced images 1, 6
  • Curved planar reformations: Following ureter course

Window Settings Summary

Structure Window Width Window Level
Soft tissue 350-400 40-50
Kidney parenchyma 300-350 50-70
Bone/Stone 2000-3000 300-500
Lung 1500 -600

Key HU Values Reference

Structure/Phase Expected HU
Unenhanced kidney 30-50
Nephrographic cortex 120-180
Nephrographic medulla 80-120
Renal artery (arterial) 300-400
Renal vein (venous) 100-150
Opacified urine 100-300
Calcium stones 400-1000+
Uric acid stones 200-500

Critical Technical Points

Common pitfalls to avoid:

  • Overscanning beyond T10 superiorly (occurs in 69% of cases) 2
  • Performing test slices for excretory timing (unnecessary—use fixed 7-minute delay) 3
  • Omitting furosemide (significantly impairs ureteral opacification) 3
  • Using split-bolus when arterial phase needed for vascular assessment 7

Dose optimization:

  • Low-dose for stones: CTDIvol 2-3 mGy 4
  • Standard for benign: CTDIvol 5-6 mGy 4
  • Malignancy protocol: CTDIvol 9-12 mGy 4
  • Split-bolus can eliminate unenhanced phase using virtual images 6

Related Questions

What brief information should I include in a presentation about the imaging modalities for the kidneys, ureters, and urinary bladder—specifically ultrasound (USS), non‑contrast computed tomography of the kidneys‑ureters‑bladder (CT KUB), contrast‑enhanced CT urography (CT urography), and magnetic resonance imaging (MRI)—including which modality is first‑line?
Can you interpret the computed tomography (CT) scan for a 67‑year‑old female with persistent left flank and lower back pain, intermittent hematuria, prior abdominal X‑ray showing intestinal air, recent cervical epidural, and no current urinary symptoms?
When is a KUB (kidney‑ureter‑bladder) radiograph appropriate for evaluating abdominal pain compared to CT imaging?
A 10‑day postpartum woman presents with dysuria and a urine culture growing mixed microbiota >100,000 CFU/mL; how should this be managed?
In a 10‑month‑old infant with a slightly indented coronal suture, normal fontanelles, and appropriate head growth, what is the appropriate next step in management?
Can pregabalin be used for alcohol withdrawal?
What are the significant drug interactions and required dosing adjustments for nintedanib, including CYP3A4 inhibitors and inducers, P‑glycoprotein inhibitors, anticoagulants, antiplatelet agents, and the effect of smoking?
What is the appropriate azithromycin dosing regimen for a 60‑kg child with a lower respiratory tract infection?
What is the appropriate amoxicillin dosage for a 60 kg child?
What are the age‑specific leukopenia cutoff values for pediatric patients?
What is the definition of partially immunized?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.